Patent application number | Description | Published |
20090214594 | Prevention and Treatment of Otitis Media with Non-Pathogenic Bacterial Strains - This invention relates to a composition comprising a bacterial strain capable of boosting the systemic immune response, a bacterial strain capable of exerting bacteriostatic effects on pathogens associated with development of otitis media such as | 08-27-2009 |
20100086527 | SYNBIOTIC TO IMPROVE GUT MICROBIOTA - The use of a probiotic strain of | 04-08-2010 |
20100119488 | PROBIOTICS TO IMPROVE GUT MICROBIOTA - The use of | 05-13-2010 |
20100119497 | PROBIOTICS TO REDUCE EPISODES OF DIARRHOEA IN INFANTS BORN BY CAESAREAN SECTION - The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for preventing or treating diarrhoea in infants delivered by caesarean section. | 05-13-2010 |
20100129335 | REDUCTION OF RISK DIARRHOEA - The use of a probiotic | 05-27-2010 |
20100150874 | PROBIOTICS TO REDUCE DEVELOPMENT OF ALLERGY IN INFANTS BORN BY CAESAREAN SECTION - The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for reducing the risk of subsequent development of allergy in infants delivered by caesarean section. | 06-17-2010 |
20100233129 | PREVENTION AND TREATMENT OF SECONDARY INFECTIONS FOLLOWING VIRAL INFECTION - This invention relates to a synthetic nutritional composition suitable for use in the prevention of secondary infections following a viral infection characterised by neuraminidase activity comprising a sialylated oligosaccharide and N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine The invention further extends to the use of such a composition in the prevention of secondary infections such as otitis media. | 09-16-2010 |
20100233198 | USE OF OLIGOSACCHARIDES CONTAINING N-ACETYLLACTOSAMINE FOR MATURATION OF IMMUNE RESPONSES IN NEONATES - This invention relates to the use of an oligosaccharide selected from the group consisting of lacto-N-tetraose, lacto-N-neotetraose, lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-hexaose, para-lacto-N-neohexaose, lacto-N-octaose, lacto-N-neooctaose, iso-lacto-N-octaose, para-lacto-N-octaose and lacto-N-decaose in the manufacture of a medicament for infants or a therapeutic nutritional composition for infants for modulating immune responses in a neonatal infant. The invention extends to the use of such an oligosaccharide for modulating the immune system of a neonatal infant to promote the development in the first few weeks of the life of the infant of a beneficial intestinal microbiota comparable with that found in breast fed infants and for reducing the risk of subsequent development of allergy in the infant. | 09-16-2010 |
20100303830 | PREVENTION AND TREATMENT OF OTITIS MEDIA USING IgA ENRICHED MILK - This invention relates to a composition suitable for use in the prevention or treatment of otitis media comprising IgA derived from mature bovine milk and having specificity for at least one of | 12-02-2010 |
20110021428 | PREVENTION OF ALLERGY AT WEANING - A nutritional composition comprising a partially hydrolysed milk protein having a degree of hydrolysis between 15 and 25% and 50 to 1000 nanograms of TGF-β per 100 ml of ready to consume composition and methods for the primary prevention of allergic reactions to newly introduced dietary protein at weaning and the prevention of development of atopic diseases in a young mammal at weaning comprising feeding to the young mammal a therapeutic amount of the composition are disclosed. | 01-27-2011 |
20110045159 | OLIGOSACCHARIDE INGREDIENT - An oligosaccharide ingredient comprising glycosylated amino acids and peptides of the general formula RnSacm where R is an amino acid residue, Sac is a monosaccharide selected from the group comprising N-acetyl-neuraminic acid, N-acetyl galactosamine and galactose, n has a value between (1) and (10) with the proviso that if n has the value (1) R is a threonine residue or a serine residue and if n has a value between (2) and (10) the peptide contains at least one threonine or serine residue, m has a value between (2) and (4) and at least (20) mol % of the ingredient is N-acetyl-neuraminic acid. | 02-24-2011 |
20110064707 | PROBIOTICS TO IMPROVE GUT MICROBIOTA - The use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for promoting the development of an early bifidogenic intestinal microbiota in infants without siblings. | 03-17-2011 |
20110110904 | NUTRITIONAL COMPOSITION CONTAINING OLIGOSACCHARIDE MIXTURE - A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligosaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life. | 05-12-2011 |
20110129452 | PROBIOTICS TO INCREASE IgA SECRETION IN INFANTS BORN BY CAESAREAN SECTION - Use of probiotic bacteria in the manufacture of a medicament or therapeutic nutritional composition for increasing IgA secretion in an infant delivered by cesarean section during the first four months of the life of the infant. | 06-02-2011 |
20110223137 | COMPOSITIONS FOR USE IN LOW-BIRTH WEIGHT INFANTS - The present invention relates to compositions for use in low-birth weight infants. In particular, the compositions are probiotic compositions which are used for achieving full enteral feeding in low birth weight infants. The invention is also concerned with the use of specific probiotics in the manufacture of low-birth weight infant formulations. | 09-15-2011 |
20110244072 | MODULATION OF INFANT FAT MASS - A method of reducing the accumulation of fat mass in a neonatal human infant at risk thereof which method comprises administering to the infant during at least a part of the neonatal period a therapeutic amount of a nutritional composition comprising proteins in an amount such that the composition contains more than 2.4 g of protein per 100 kcal. As weight gain during the first week of life has been associated with overweight in adulthood, this may offer a method of reducing the risk of developing obesity in later life. Also claimed is the administration of DHA to the mother during gestation period. | 10-06-2011 |
20120045566 | OLIGOSACCHARIDE INGREDIENT - An oligosaccharide ingredient comprising glycosylated amino acids and peptides of the general formula RnSacm where R is an amino acid residue, Sac is a monosaccharide selected from the group comprising N-acetyl-neuraminic acid, N-acetyl galactosamine and galactose, n has a value between 1 and 10 with the proviso that if n has the value 1 R is a threonine residue or a serine residue and if n has a value between 2 and 10 the peptide contains at least one threonine or serine residue, m has a value between 2 and 4 and at least 20 mol % of the ingredient is N-acetyl-neuraminic acid. | 02-23-2012 |
20130131014 | PREVENTION AND TREATMENT OF SECONDARY INFECTIONS FOLLOWING VIRAL INFECTION - This invention relates to a synthetic nutritional composition suitable for use in the prevention of secondary infections following a viral infection characterised by neuraminidase activity comprising a sialylated oligosaccharide and N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine. The invention further extends to the use of such a composition in the prevention of secondary infections such as otitis media. | 05-23-2013 |
20130165374 | PREVENTION OF ALLERGY AT WEANING - A nutritional composition comprising a partially hydrolysed milk protein having a degree of hydrolysis between 15 and 25% and 50 to 1000 nanograms of TGF-β per 100 ml of ready to consume composition and methods for the primary prevention of allergic reactions to newly introduced dietary protein at weaning and the prevention of development of atopic diseases in a young mammal at weaning comprising feeding to the young mammal a therapeutic amount of the composition are disclosed. | 06-27-2013 |
20130224331 | NUTRITIONAL COMPOSITION CONTAINING OLIGOSACCHARIDE MIXTURE - A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligasaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto- oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosacchardide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life. | 08-29-2013 |
20150030720 | NUTRITIONAL COMPOSITION CONTAINING OLIGOSACCHARIDE MIXTURE - A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt % of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligosaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt % of an N-acetylated oligosaccharide, at least 2.0 wt % of a galacto-oligosaccharide and at least 0.04 wt % of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto-oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life. | 01-29-2015 |